---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-000112"
form_type: "8-K"
ticker: "BCRX"
cik: "0000882796"
company_name: "BIOCRYST PHARMACEUTICALS INC"
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:47:08.707499+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# BioCryst announces FY2023 ORLADEYO revenue $325M (+29%), 2024 guidance $380-400M, sees operating profit in 2024

## Summary
- Preliminary Q4 ORLADEYO net revenue $89.9M (+27% YoY); full-year 2023 $325M (+29% YoY).
- 2024 ORLADEYO revenue guidance $380-400M; company reaffirms peak sales target of $1B.
- 2024 operating expenses expected flat at $365-375M; R&D reduced $20M vs 2023.
- Restructuring reduces workforce by 59 jobs (10%); plans to out-license BCX10013 if data supports.
- ORLADEYO WAC increased ~5% to $42,366 per 28-day pack, effective January 8, 2024.

## SEC filing metadata
- accession: 0001171843-24-000112
- form_type: 8-K
- ticker: BCRX
- cik: 0000882796
- company_name: BIOCRYST PHARMACEUTICALS INC
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882796/000117184324000112/0001171843-24-000112-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882796/000117184324000112/f8k_010824.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-000112
- JSON: https://secwatch.observer/filing/0001171843-24-000112.json
- Plain text: https://secwatch.observer/filing/0001171843-24-000112.txt

## Key facts
- Earnings Releases
  BIOCRYST PHARMACEUTICALS INC reported full year 2024 results: revenue 380-400. Guidance reaffirmed.
  - Period: full year 2024
  - Revenue: 380-400
  - Guidance: reaffirmed
  - Result: guidance update
  source text: Guidance and Accelerated Path to Profitability —ORLADEYO preliminary 2023 full year net revenue of $325 million (+29 percent y-o-y)— —ORLADEYO net revenue expected to be between $380-$400 million in 2024, on trajectory for $1 billion in peak sales— —Operating expenses expected to remain flat ($365-$375 million) in 2024— —Company expects operating profit in
  evidence_url: https://www.sec.gov/Archives/edgar/data/882796/000117184324000112/0001171843-24-000112-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.